Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fosrolapitant-palonosetron plus olanzapine with or without dexamethasone for prevention of highly emetogenic chemotherapy-induced nausea and vomiting
ChiCTR2600132373Phase 4Not yet recruiting
- Sponsor
- Ya'an People's Hospital
- Start
- Aug 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of fosrolapitant, palonosetron, olanzapine and dexamethasone in Nausea and Vomiting and chemotherapy-induced nausea and vomiting (CINV) (2 cohorts), sponsored by Ya'an People's Hospital. Primary endpoint: Complete response rate. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
fosrolapitantpalonosetronolanzapinedexamethasone
03
Conditions
Nausea and Vomitingchemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on ChiCTR2600132373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600132373.